[Risk of osteoporosis in postmenopausal women. When is bone density measurement indicated?].
D015502:Absorptiometry, Photon; D000368:Aged; D019386:Alendronate / Q000627:therapeutic use; D015519:Bone Density / Q000187:drug effects; D012968:Etidronic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D005598:Fractures, Spontaneous / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000175:diagnosis* / Q000209:etiology; D017410:Practice Guidelines as Topic; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D000068296:Risedronic Acid; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use; D016103:Spinal Fractures / Q000209:etiology / Q000517:prevention & control
D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride; D000068296:Risedronic Acid; D012968:Etidronic Acid; D019386:Alendronate
Osteoporoserisiko bei postmenopausalen Frauen. Wann ist die Knochendichte-Messung angezeigt?